Molecular features of clinical outcomes in men with localized intermediate-risk prostate cancer treated with pre-operative apalutamide

Molecular features of clinical outcomes in men with localized intermediate-risk prostate cancer treated with pre-operative apalutamide

Bibliographic Details
Main Authors:	J. Davis, AHN Hahn, GCM Manyam, BFC Chapin, MZ Zhang, YY Yu, CAP Pettaway, LC Chery, LLP Pisters, JFW Ward, JRG Gregg, JP Papadopoulos, ML Lozano, AH Hoang, BB Broom, XW Wang, CDH Huff, CJL Logothetis, PT Troncoso, PGP Pilie
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168324002817

Similar Items

Apalutamide-induced ichthyosiform eruption
by: Christian Ciolfi, et al.
Published: (2023-08-01)

Psoriatic Skin Lesions after Apalutamide Treatment
by: Fumi Miyagawa, et al.
Published: (2022-02-01)

[Translated article] RF-Adverse Skin Reaction to Apalutamide: An Emerging Effect
by: M. Pons Benavent, et al.
Published: (2023-04-01)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
by: Nora A. Alkhudair
Published: (2019-03-01)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
by: Gul A, et al.
Published: (2019-08-01)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
by: Maria De Santis, et al.
Published: (2019-04-01)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
by: Gustavo Werutsky, et al.
Published: (2019-05-01)

Case report: Apalutamide-induced severe lethal cutaneous adverse effects in China
by: Qi Wang, et al.
Published: (2024-01-01)

Apalutamide for prostate cancer: Multicentre and multidisciplinary real‐world study of 227 patients
by: Julián Córdoba Sánchez, et al.
Published: (2023-12-01)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
by: Harkirat Singh Talwar
Published: (2021-01-01)

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
by: Vadim S. Koshkin, et al.
Published: (2018-12-01)

Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer
by: Tomoko Honda, et al.
Published: (2022-11-01)

Apalutamide‐associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy
by: Yoichiro Tohi, et al.
Published: (2021-09-01)

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial
by: Byung Ha Chung, et al.
Published: (2023-01-01)

Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
by: Takashi Ueda, et al.
Published: (2024-01-01)

Targeting Metabolic Vulnerabilities to Overcome Prostate Cancer Resistance: Dual Therapy with Apalutamide and Complex I Inhibition
by: Valentin Baumgartner, et al.
Published: (2023-11-01)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
by: Carlo Cattrini, et al.
Published: (2022-03-01)

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of <i>Pten</i>-Deficient Prostate Cancer
by: Marco A. De Velasco, et al.
Published: (2021-08-01)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
by: Zhihong Fang, et al.
Published: (2023-06-01)

Bioequivalence clinical trial simulation: a case study of apalutamide administered in applesauce versus whole tablets
by: Alex Yu, et al.
Published: (2023-08-01)

Efficacy and safety of apalutamide with high-volume mHSPC: Real-world experience from three cases
by: Jingqi Jiang, et al.
Published: (2023-09-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)

Absence of PSA Flare With Apalutamide Administered 1 Hour in Advance With GnRH Agonists: Case Report
by: Zhiquan Hu, et al.
Published: (2022-05-01)

Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial
by: Byung Ha Chung, et al.
Published: (2022-01-01)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
by: Sambit Tripathy
Published: (2021-01-01)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
by: Yongbao Wei, et al.
Published: (2023-10-01)

Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells
by: Amene Majidipur, et al.
Published: (2023-02-01)

Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair
by: Wenhao Zhang, et al.
Published: (2019-10-01)

Toxic Epidermal Necrolysis Caused by Apalutamide: A Case Report of Treatment Using Etanercept with Conventional Steroid Therapy
by: Kana Osawa, et al.
Published: (2022-05-01)

Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case
by: Fumiaki Kirishima, et al.
Published: (2022-05-01)

Editorial Comment to Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case
by: Takeshi Yuasa
Published: (2022-05-01)

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
by: Arif Hussain, et al.
Published: (2022-03-01)

Apalutamide-Induced Toxic Epidermal Necrolysis in a Caucasian Patient with Metastatic Castration-Sensitive Prostate Cancer: A Case Report and Review of the Literature
by: Calvin R. Flynn, et al.
Published: (2023-08-01)

Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial
by: Masato Fujisawa, et al.
Published: (2023-03-01)

Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study
by: Alicia López-Abad, et al.
Published: (2024-03-01)

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
by: Lorenzo Tosco, et al.
Published: (2018-04-01)

Patient-reported outcomes of neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial – a phase II trial
by: X.Y. Yang, et al.
Published: (2020-07-01)

R.B. Halbertsma, Le solitaire des ruines. De archeologische reizen van Jean Emile Humbert (1771-1839) in dienst van het Koninkrijk der Nederlanden
by: P.G.P. Meyboom
Published: (1997-01-01)

R.B. Halbertsma, Le solitaire des ruines. De archeologische reizen van Jean Emile Humbert (1771-1839) in dienst van het Koninkrijk der Nederlanden
by: P.G.P. Meyboom
Published: (1997-01-01)

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial
by: Dingyuan Yang, et al.
Published: (2023-11-01)